Projecting future drug expenditures--2010

Hoffman, James M.; Doloresco, Fred; Vermeulen, Lee C.; Shah, Nilay D.; Matusiak, Linda; Hunkler, Robert J.; Schumock, Glen T.
June 2010
American Journal of Health-System Pharmacy;6/1/2010, Vol. 67 Issue 11, p919
Academic Journal
Purpose. Drug expenditure trends in 2008 and 2009, projected drug expenditures for 2010, and factors likely to influence drug expenditures are discussed. Summary. Various factors are likely to influence drug expenditures in 2010, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, drug safety concerns, and comparative effectiveness research. The increasing availability of important generic drugs continues to moderate growth in drug expenditures. Health care reform initiatives, including the potential for biosimilars legislation, will influence drug expenditures in all settings. From 2007 to 2008, total U.S. drug expenditures increased by 1.8%, with total spending rising from $279.6 billion to $284.7 billion. Growth in drug expenditures in clinics declined to the lowest level in a decade, a 1.0% increase from 2007 to 2008. Hospital drug expenditures increased at a moderate rate of only 2.1% from 2007 to 2008; through the first nine months of 2009, hospital drug expenditures increased by 3.0% compared with the same period in 2008. Conclusion. In 2010, we project a 3-5% increase in drug expenditures in outpatient settings, a 6-8% increase in expenditures for clinic-administered drugs, and a 2-4% increase in hospital drug expenditures.


Related Articles

  • Balancing Business & National Health: The Impact of Legislation on Pharmaceutical Drug Prices. Rosen, Davina // Temple Journal of Science, Technology & Environmental Law;2007, Vol. 26 Issue 2, p341 

    The article shows how different institutions have addressed the issue of expensive medical costs to make drugs more affordable. It describes the federal system that seeks to encourage the pharmaceutical industry to develop innovative drugs and protect them when their products are already...

  • Reimbursements for Imported Prescription Drugs.  // Clergy Journal;Feb2005, Vol. 81 Issue 4, p26 

    The article announces U.S. government policy on imported prescription drugs. The Internal Revenue Service has reaffirmed its position on imported prescription drugs. Schedule A deductions for prescription drugs bought abroad are only available if the drug is legal in the country where it is...

  • The Long Road to Generics.  // Pharmaceutical Executive;Jan2005, Vol. 25 Issue 1, pS7 

    This article reports that Mexico was the first Latin American country to pass a law in order to stimulate and regulate the development of quality and efficient generics, qualified as Genericos Intercambiables or Gis (for Inter Exchangeable Generic). The law was very clear in its definitions: GIs...

  • Canadian price controls destroying market competition.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p10 

    Reports on the impact of pharmaceutical price controls imposed by Canadian authorities on market competition. Effect of the pharmaceutical policy on healthcare spending in the country; Criticism against high prices of generic drugs in Canada compared with the U.S.; Average amount spent by...

  • Final Rule for Generic Reporting Withdrawn. Drakulich, Angie // Pharmaceutical Technology;Mar2009, Vol. 33 Issue 3, p37 

    The article reports on the withdrawal of the U.S. Food and Drug Administration (FDA) on its final rule on Reporting Information About Authorized Generic Drugs initiative. This initiative would require drug makers disclosure on authorized generic drugs on their annual new drug application reports...

  • Abu Dhabi moves towards generic prescribing.  // PharmaWatch: Monthly Review;Jun2009, Vol. 8 Issue 6, p39 

    The article reports on the move of the Health Authority of Abu Dhabi in United Arab Emirates towards prescription of generic drugs in the country. It notes that Health Authority of Abu Dhabi also forces doctors throughout the area to use generic drugs by molecular name. However, the law in the...

  • Expiry of medicines in supply outlets in Uganda. Nakyanzi, Josephine Katabaazi; Kitutu, Freddy Eric; Oria, Hussein; Kamba, Pakoyo Fadhiru // Bulletin of the World Health Organization;Feb2010, Vol. 88 Issue 2, p154 

    Problem The expiry of medicines in the supply chain is a serious threat to the already constrained access to medicines in developing countries. Approach We investigated the extent of, and the main contributing factors to, expiry of medicines in medicine supply outlets in Kampala and Entebbe,...

  • Rx's role in health care reform. Woldt, Jeffrey // Chain Drug Review;10/26/2009, Vol. 31 Issue 18, p22 

    The article discusses the role played by physicians in health care reform in the U.S. It cites Tom Ryan, chief executive officer (CEO) of CVS Caremark Corp., who urged the Congress to apply to public policy to increase government support for businesses involved in wellness, drug adherence...

  • Safety Concerns About Possible Drug Imports Are Reiterated.  // Chain Drug Review;8/3/2009, Vol. 31 Issue 13, p113 

    The article focuses on the effort of the Pharmaceutical Research and Manufacturers of America (PhRMA) to oppose the policy allowing reimportation of drugs to be a key component of health care reform in the U.S. According to PhRMA, it is important to keep focus on comprehensive health reform to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics